Bronconex Acticap

国家: 新西兰

语言: 英文

来源: Medsafe (Medicines Safety Authority)

有效成分:

Mometasone furoate 400ug (anhydrous)

可用日期:

Organon (New Zealand) Limited

INN（国际名称）:

Mometasone furoate 400 µg (anhydrous)

剂量:

400 mcg/dose

药物剂型:

Powder for inhalation

组成:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

每包单位数:

Inhaler, metered, DPI, (sample), 14 dose units

类:

Prescription

处方类型:

Prescription

厂商:

MSD International GmbH (Singapore Branch)

疗效迹象:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

產品總結:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

授权日期:

2000-12-05